Đang chuẩn bị liên kết để tải về tài liệu:
Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Due to recent concerns about the toxicity of trastuzumab emtansine (T-DM1) with stereotactic radiation, we assessed our institutional outcomes treating HER2-positive breast cancer brain metastases (BCBM) with T-DM1 and stereotactic radiation. |

TÀI LIỆU LIÊN QUAN

Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: A case report

Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells

High score of LDH plus dNLR predicts poor survival in patients with HER2- positive advanced breast cancer treated with trastuzumab emtansine

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases

Real-world effectiveness of posttrastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: A retrospective observational study (KBCSGTR 1917)

Determination of cellular processing rates for a Trastuzumab-Maytansinoid antibody-drug conjugate (ADC) highlights key parameters for ADC design

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: A systematic review and meta-analysis

Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review